RxDoctor Payments Data

Misha Basalaev, MD

Internal Medicine · East Brunswick, NJNPI 1144268137

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by AbbVie at 42.5% of the total.

$693in general payments, 2019–2025

Across 7 payments — averaging $99.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$295
  • Novo Nordisk$150
  • AstraZeneca$125
  • Ironwood Pharmaceuticals, Inc$124

What the payments were for

  • Food & beverage$693100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)3$295
Novo Nordisk2$150
AstraZeneca1$125
Ironwood Pharmaceuticals, Inc1$124

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$693 in reported general payments places this provider in the 60th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$215,433
Medicare patients
292
Services billed
1,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$58,665
JanuviaSitagliptin Phosphate33$30,845
Nicotrol NsNicotine12$23,831
XareltoRivaroxaban14$20,232
MyrbetriqMirabegron12$12,555
CymbaltaDuloxetine Hcl24$9,801
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid30$7,718
SynthroidLevothyroxine Sodium57$4,577
Nebivolol Hcl54$4,080
Levothyroxine Sodium277$3,558
Lidocaine26$3,508
Acetaminophen-CodeineAcetaminophen With Codeine71$3,090
Atorvastatin Calcium256$2,925
Rosuvastatin Calcium185$2,865
SymbicortBudesonide/Formoterol Fumarate13$2,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$295$4,57757 claims
AstraZenecaSymbicort$125$2,63513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in East Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →